65 results about "Antibody screening" patented technology

This invention discloses a camel-derived CRP single-domain antibody, its preparation method, and its applications, relating to the biomedical field. The method involves enriching CRP antigen in alpaca leukocytes immunized with the antigen, followed by single-cell screening and sequencing. Through sequencing structural analysis, a recombinant plasmid of the camel-derived CRP antibody is constructed. This plasmid is cloned and transformed into eukaryotic cells to express related antibodies. Monoclonal antibodies with human CRP resistance are screened for expression. The VHH domain of the monoclonal antibody is cloned and expressed, and paired screening yields CRP-VHH monoclonal antibodies with antibody activity. This antibody can be used in ELISA kits, chemiluminescence kits, and latex kits, possessing the same functionality as existing kits. Furthermore, this antibody also has applications in the preparation of antitumor drugs.

The invention provides a disease marker epitope prediction and antibody screening method, which belongs to the technical field of disease markers, and comprises the following steps: firstly, establishing a training data set containing a known antigen-antibody compound structure and disease tissue expression data; and obtaining target protein sequence information through liquid chromatography-mass spectrometry analysis and carrying out sequence comparison. And then a deep convolutional neural network is utilized to extract sequence features, and surface exposure sites are identified by combining secondary structure prediction and solvent accessibility analysis. After the features are integrated with sequence evolution conservative properties, a prediction model is constructed by using a random forest classifier. The method comprises the following steps: carrying out molecular dynamics simulation on a prediction result, screening first 10% of candidate sequences through a comprehensive scoring function and K-means clustering, and finally determining an antigen epitope sequence with the strongest binding activity through verification of an antigen chip and a fluorescence labeled antibody system, so that the technical problem that specific antigen epitopes are difficult to accurately predict and recognize in the prior art is solved.

The invention relates to an erythrocyte specific antibody screening test kit expressing a single antigen from a target erythrocyte (RBC) antigen (RhD and RhCE as 2 different antigens derived from RBC and 45 or more antigens in total including some variants of these two antigens) and a preparation method of this test kit. Said antigens are transgenically produced and provide the clearest results compared to traditional methods of antibody screening. Field-targeted mutation process is applied during the preparation of the erythrocyte-specific antibody screening test kit subject to the invention.

Herein is reported a method for preparing a recombinant host cell library expressing bispecific antibodies using targeted integration into a host cell comprising an exogenous nucleotide sequence integrated at a site within a locus of the genome of the host cell, wherein the exogenous nucleotide sequence comprises a first and a second recombination recognition sequence flanking at least one first selection marker, and a third recombination recognition sequence located between the first and the second, recombination recognition sequence, and all the recombination recognition sequences are different whereby the host cell is transfected with a library of first vectors each comprising two recombination recognition sequences matching the first and the third recombination recognition sequence on the integrated exogenous nucleotide sequence and flanking two exogenous nucleotide sequences and at least one second selection marker, and a library of second vectors each comprising two recombination recognition sequences matching the second and the third recombination recognition sequence on the integrated exogenous nucleotide sequence and flanking at least two further exogenous nucleotide sequences; wherein one of the four exogenous nucleotide sequences encode a first light chain, one a second light chain, one a first heavy chain and one a second heavy chain of the bispecific antibody.

The invention relates to the field of antibodies, and particularly provides a high-affinity PADI2 antibody and a preparation method thereof. According to the invention, eight high-affinity PADI2 antibodies are obtained by screening through an antibody pair screening experiment, and the antibodies can be specifically combined with PADI2 protein and have high affinity. Experimental results show that the antibody disclosed by the invention shows excellent binding capacity in ELISA (Enzyme-Linked Immunosorbent Assay), Western blot and cell experiments, and can be used for detecting, diagnosing and treating PADI2 related diseases.

The application discloses a CRP camel-derived single-domain antibody and a preparation method and application thereof, relates to the field of biological medicines, and is characterized in that: white blood cells of a llama immunized with a CRP antigen are enriched, and then single-cell screening and sequencing are performed. Through sequencing structure analysis, a camel-derived CRP antibody recombinant plasmid is constructed, a related antibody is expressed in a eukaryotic cell through cloning transformation, a single antibody with human CRP resistance is screened, a VHH domain of the single antibody is cloned and expressed, and a single antibody with CRP-VHH antibody activity is obtained through pairing screening. The antibody can be applied to an ELISA kit, a chemiluminescence kit and a latex kit, has the same functions as existing kits, and still has the use in the preparation of an anti-tumor drug.

The invention discloses a real-time detection system and a monitoring and early warning method for African swine fever virus. The system comprises a latex microsphere labeled immunochromatography antibody detection card, a portable MINI-PCR instrument and a freeze-dried microsphere type fluorescent PCR detection reagent, the detection card takes the recombinant ASFV p30 protein as a target spot, antibody detection is completed within 10 minutes, the lowest detection limit is 1: 1024, and the specificity is greater than 99%; the PCR reagent adopts a double-primer double-probe design, and the lowest detection limit is 1 copy / microliter. According to the invention, through a collaborative process of antibody screening, nucleic acid detection and result evaluation, ASFV total infection cycle detection is realized, epidemic situation discovery time is advanced to 1-3 days after infection, and early warning response time is shortened by more than 60%; the system is simple to operate and low in cost, does not need professionals and laboratories, can be deployed in basic-level scenes such as pig farms and slaughter houses, effectively solves pain points of an existing detection system, and provides key technical support for prevention and control of African swine fever.

The application relates to the technical field of biological medicine, and provides an anti-GPC3 full humanization single-domain antibody and application thereof. The application uses phage display technology to obtain one anti-human GPC3 specificity full humanization monoclonal single-domain antibody through antibody screening by targeting human GPC3 protein. The obtained single-domain antibody can be specifically combined with human GPC3, and can effectively inhibit the nuclear translocation of YAP, provides an effective alternative antibody drug for GPC3-targeted HCC treatment, and has a potential clinical application prospect.

The invention discloses a risk assessment system for difficulty in cross matching of blood, and relates to the technical field of clinical medical examination and blood transfusion management. The system comprises a data input module, a risk calculation module, a risk layering module and a result output and suggestion module. The data input module obtains key information of a patient, wherein the key information comprises an erythrocyte irregular antibody screening result, multiple myeloma diagnosis, hematology department medical history, age of more than or equal to 60 years, pregnancy-related disease state and blood type identification difficulty; the risk calculation module adopts a preset scoring algorithm to endow each factor with a weight and calculates a total risk score; the risk layering module divides the patients into three levels of low risk, medium risk and high risk; and the result output module provides differentiated clinical management paths corresponding to the risk levels. According to the method, early warning of difficulty in cross matching of blood is achieved through quantitative evaluation, blood transfusion process efficiency can be optimized, clinical risks can be reduced, and the method has good prediction performance (AUC = 0.819) and a high negative prediction value (93.7%).

The invention belongs to the technical field of bioengineering, and particularly relates to a preparation method and application of a calprotectin S100A8 / A9 dimer mouse monoclonal antibody, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO. 28-30. According to the present invention, the S100A8 / A9 heterodimer protein with biological activity and immunostimulation function is prepared, the protein is used to immunize mice, the specific gene engineering antibody of the S100A8 / A9 heterodimer protein is prepared, the antibody pair with high sensitivity is screened, and the calprotectin S100A8 / A9 double-antibody sandwich enzyme-linked immunosorbent assay method is preliminarily developed;

1. The name of the design product: full-automatic blood type analyzer. 2. The use of the design product: using column agglutination method, together with the matching detection reagent, for ABO system blood type typing, Rh system blood type typing, irregular antibody screening, cross matching and direct anti-human globulin test on human blood samples in clinical application. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The application discloses a kind of based on HIV envelope protein chimeric exosome and its preparation method and application, belong to biological medicine technical field.The application first constructs the cell line of stable expression HIV envelope protein Env, obtains engineered exosome from cell culture supernatant separation and purification;The exosome is used as immunogen combined with adjuvant immunization experimental animal, and high-efficiency induction specific humoral immune response;Again, obtain Env antigen specificity single B cell by flow cytometry sorting, obtain antibody variable region gene by single cell lysis, reverse transcription and nest PCR amplification, cloning to expression vector and expressing in mammalian cell, finally, HIV specific neutralizing antibody is screened by binding activity, affinity and neutralizing activity;The application is combined with single B cell antibody screening technology by embedding HIV Env antigen in the form of membrane combination in exosome surface, and realizes the synergistic optimization of antigen delivery and antibody screening process.

The present application relates to the technical field of biotechnology, in particular to a monoclonal antibody against A29L protein of monkeypox virus and application thereof. The present application prepares the monoclonal antibody against A29L protein of monkeypox virus, and through optimization of antibody screening and expression technology, the antibody with high affinity and high specificity is screened, and then a new tool is provided for rapid detection, effective neutralization and treatment of monkeypox virus, and an important immunological basis is provided for vaccine research and development and treatment scheme design of monkeypox virus.

The present invention relates to a method of detecting intermolecular interaction kinetics, the method comprising a first molecule and a second molecule to be analyzed, dispersing the first molecule in a solution as a detection solution, attaching the second molecule to a biosensor and being freely translatable over the surface of the sensor; the biosensor comprises a tethered bilayer phospholipid membrane and a solid conductive surface, a lower layer membrane of the tethered bilayer phospholipid membrane is fixed, and an upper layer membrane of the tethered bilayer phospholipid membrane can freely translate; the phospholipid membrane contains ion channel protein; and contacting the detection solution with the biosensor, detecting the conductivity change of the tethered bilayer phospholipid membrane, and analyzing the interaction kinetics of the first molecule and the second molecule. The method for detecting intermolecular interaction kinetics based on tethered bilayer phospholipid membrane and ion channel switch technology development can realize accurate quantitative detection in a wide concentration range, does not need sample flow, and is suitable for the fields of antibody screening, drug screening and life science.

According to the invention, blood group antigens suitable for allogenic blood transfusion detection are screened and combined, and blood group antibody selection, fluorescent antibody screening, automatic cell cleaning program control, cleaning fluid selection, erythrocyte aggregation resistance, allogenic erythrocyte determination and other multi-condition combination methods are adopted. The detection rate of the positive sample of the allogenic blood transfusion stimulant is further effectively improved, and the accuracy of allogenic blood transfusion detection is improved.

The present application relates to the field of antibodies, and in particular, the present application provides a high affinity PADI2 antibody and a preparation method thereof. Through antibody screening experiments, eight high affinity PADI2 antibodies are screened, the antibodies can specifically bind to PADI2 protein, and have high affinity. Experimental results show that the antibodies of the present application exhibit excellent binding capacity in ELISA, Western blot and cell experiments, and can be used for detection, diagnosis and treatment of PADI2 related diseases.

The invention discloses a rapid detection method for fusarium moniliforme based on nano-antibody targeted recognition, and relates to the technical field of plant disease detection.The detection method comprises the steps of nano-antibody screening and compound preparation, specifically, antigen protein is extracted from fusarium moniliforme, a camel is selected as an immune animal for immune treatment, and a compound is obtained; separating lymphocytes to construct a nano antibody gene pool; through nano antibody screening and compound preparation technologies, the sensitivity and the specificity of detection of the rice fusarium moniliforme are remarkably improved, antigen protein is extracted from the rice fusarium moniliforme, a camel is selected as an immune animal for immune treatment, a nano antibody gene pool is constructed, and the sensitivity and the specificity of detection of the rice fusarium moniliforme are improved. Nano antibodies with high affinity and specificity are screened out by utilizing a phage display technology, and the nano antibodies can accurately recognize and combine specific epitopes of pathogenic bacteria, so that the problem of cross reaction possibly existing in traditional antibodies is avoided.

The application discloses a risk assessment system for cross matching difficulty, and relates to the technical field of clinical medical examination and blood transfusion management. The system comprises a data input module, a risk calculation module, a risk stratification module and a result output and suggestion module. The data input module obtains key information of a patient, including irregular red blood cell antibody screening results, multiple myeloma diagnosis, hematology department medical history, age of 60 years or older, pregnancy-related disease state and blood type identification difficulty; the risk calculation module adopts a preset scoring algorithm to assign weights to each factor and calculate a total risk score; the risk stratification module divides the patient into three grades of low risk, medium risk and high risk; and the result output module provides a differentiated clinical management path corresponding to the risk grade. The application realizes early warning of cross matching difficulty through quantitative assessment, can optimize the efficiency of the blood transfusion process and reduce clinical risk, has good prediction performance (AUC=0.819) and a high negative predictive value (93.7%).

The invention discloses a non-human animal integrated with a double-derived VH subclass fusion gene as well as a construction method and application of the non-human animal. The method comprises the following steps: firstly, constructing a gene construct containing human IGHV1-69 and IGHV3-23 fragments, a specific spacer region, a functional element and a rat heavy chain 3'enhancer, and microinjecting the gene construct into a C57BL / 6J fertilized egg with an endogenous heavy chain and a kappa light chain knocked out to obtain a transgenic mouse; through identification, after a mouse endogenous antibody is inactivated, a human gene is stably integrated, a human IgM antibody is expressed and H5N1 HA immunization is carried out, the use frequency of IGHV1-69 is remarkably increased, the mouse produces a high-titer specific antibody, and serum has neutralizing activity. The mouse can generate a target bnAbs aiming at the HA stem and the RBS in parallel, so that the antibody screening efficiency is improved, and an in-vivo screening and evaluation platform for simulating human body fluid response is provided for research and development of influenza antibodies and vaccines.

The invention relates to the field of antibodies, and particularly provides a high-affinity PADI2 antibody and a preparation method thereof. According to the invention, eight high-affinity PADI2 antibodies are obtained by screening through an antibody pair screening experiment, and the antibodies can be specifically combined with PADI2 protein and have high affinity. Experimental results show that the antibody disclosed by the invention shows excellent binding capacity in ELISA (Enzyme-Linked Immunosorbent Assay), Western blot and cell experiments, and can be used for detecting, diagnosing and treating PADI2 related diseases.

The invention provides a membrane-like system containing FGFR (Fibroblast Growth Factor Receptor), a phospholipid bilayer and membrane skeleton protein and a preparation method of the membrane-like system, and particularly relates to a method for assembling a nanodisk (nanodisk) by using the FGFR and application of the nanodisk containing the FGFR in the aspects of antibody screening and drug screening.

The present application belongs to the technical field of biological detection, and particularly relates to a non-invasive selenium level prediction method based on saliva selenoprotein P detection and application. The present application immunizes mice with heterologously expressed antigen SELENOP (40-194 aa) to generate antibodies, and monoclonal antibodies capable of efficiently recognizing SELENOP are screened and obtained; an ELISA detection method is established using the obtained monoclonal antibodies. The selenium content in human plasma and saliva is detected and analyzed using the detection method and an ICP-MS selenium content detection method, and it is found that there is a significant positive correlation between the three, and a correlation curve between saliva selenoprotein P and human plasma selenium content is established, thereby achieving the purpose of evaluating human selenium level through non-invasive saliva selenoprotein P detection. The technical scheme provided by the present application can be used for large-scale screening and routine health monitoring.

The present application relates to the field of antibodies, and in particular, the present application provides a high affinity PADI2 antibody and a preparation method thereof. Through antibody screening experiments, eight high affinity PADI2 antibodies are screened, the antibodies can specifically bind to PADI2 protein, and have high affinity. Experimental results show that the antibodies of the present application exhibit excellent binding capacity in ELISA, Western blot and cell experiments, and can be used for detection, diagnosis and treatment of PADI2 related diseases.

The application discloses a novel coronavirus neutralizing antibody, a detection kit and application thereof, an amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No. 1, and an amino acid sequence of a light chain variable region is shown as SEQ ID No. 2. The application screens the affinity-matured antibody through bioinformatics analysis of a single B cell, combines single-cell RNA sequencing, VDJ rearrangement analysis and somatic hypermutation research, optimizes the antibody screening process, avoids blindness of a traditional method, and improves the accuracy and effectiveness of antibody screening. The neutralizing antibody GR58 provided by the application can specifically combine with a RBD domain of SARS-CoV-2 and a S-Trimer domain of an Omicron mutant strain through the heavy chain and light chain variable regions, realizes broad-spectrum neutralization of SARS-CoV-2 and mutant strains thereof, and the antibody GR58 is significantly superior to other antibodies in the binding activity of S-Trimer and RBD under 2-fold and 300-fold dilution conditions, indicating that the antibody has high affinity and dilution stability, and is suitable for clinical large-dose administration requirements.

The invention relates to the technical field of biology, in particular to a monoclonal antibody for resisting monkey pox virus A29L protein and application of the monoclonal antibody. The monoclonal antibody aiming at the monkey pox virus A29L protein is prepared, and the antibody with high affinity and high specificity is screened by optimizing an antibody screening and expression technology, so that a new tool is provided for rapid detection, effective neutralization and treatment of the monkey pox virus; and an important immunological basis is provided for vaccine research and development of the monkey pox virus and design of a treatment scheme.

Specifically, the present invention relates to a humanized monoclonal antibody efficiently neutralizing a SARS-CoV-2 variant strain and a use thereof. Six CDR regions of the antibody are as shown in SEQ ID NOs: 1-6; a heavy chain variable region of the monoclonal antibody has a full length of an amino acid sequence as shown in SEQ ID NO: 7; and a light chain variable region of the monoclonal antibody has a full length of an amino acid sequence as shown in SEQ ID NO: 8. By using B-cell culture combined with antibody cloning technology and by means of a cross-reactive antibody screening strategy, a human monoclonal antibody 2F8 with efficient neutralization activity is obtained from a patient having recovered from original SARS-CoV-2 infection. The antibody can effectively resist neutralization escape by the SARS-CoV-2 variant strain and can be used for passive prevention in a population at a high risk of SARS-CoV-2 infection and the treatment of COVID-19.

The present invention relates to chimeric polypeptides comprising a scaffold polypeptide and one or more exogenous polypeptides, wherein the scaffold polypeptide comprises a backbone protein 2a (BP-2a) Domain 3 (D3) polypeptide in which at least one endogenous loop has been partially or wholly replaced by an exogenous polypeptide. The present invention also relates to nanoparticles, outer membrane vesicles, pharmaceutical compositions, vaccines, arrays and kits comprising said chimeric polypeptides, methods of their production, and uses thereof in therapy and antibody screening.

The invention discloses a blood group reagent quality control kit and application thereof, the blood group reagent quality control kit comprises a plurality of independently subpackaged composite quality control products, and each quality control product simultaneously comprises quality control red blood cells with known antigen spectra and quality control plasma with known antibody spectra; the quality control red blood cells are human red blood cells with known ABO blood type, RhD blood type and Rh haplotype; the quality control plasma contains blood group antibodies with known specificity and immune globulin types, and the blood group antibodies comprise IgM antibodies and / or IgG antibodies. The invention also discloses application of the blood group reagent quality control kit in indoor quality control of blood group serology detection and an indoor quality control method of blood group serology detection. The kit provided by the invention can realize integrated and efficient detection, and synchronously complete indoor quality control of a plurality of core items such as blood type identification, antibody screening, cross matching of blood and the like.

The utility model discloses a cell culture and detection device for rapidly screening antibodies. The device comprises a detection capacitor chip, an accommodating structure and a culture room, the detection capacitor chip comprises a planar chip main body, a first electrode and a second electrode, and the surface of the first electrode is covered with a protein antigen layer; the accommodating structure is arranged on the first surface and is tightly combined with the non-detection area of the first electrode to form a culture cavity, and the protein antigen layer is exposed in the culture cavity; the culture chamber is arranged in the culture cavity, and at least part of the chamber wall is provided with micropores. According to the utility model, the flexible nano biochip sensing technology is utilized to realize high-precision synchronous real-time monitoring on the change of the capacitance value of the chip, and the detection sensitivity is high, so that cells secreting positive antibodies can be quickly identified and screened out; according to the pure electrical detection mode, a large amount of invalid waiting time and detection time caused by enzyme-linked immunosorbent assay in the hybridoma screening process in the traditional microscopic imaging technology are eliminated, and the antibody screening efficiency is greatly improved.

The utility model belongs to the technical field of anti-sperm antibody screening, and discloses an anti-sperm antibody screening device which comprises a vessel upper cover, the vessel upper cover comprises a check ring fixed to the top face, a plurality of clamping positions are fixedly arranged on the outer side of the check ring, clamping strips are fixedly arranged in the clamping positions, and the clamping strips are connected with the check ring. An L-shaped clamping groove is formed in the outer side of the clamping strip in a clamped mode, a movable clamping plate is fixedly arranged on the outer side of the L-shaped clamping groove, a vessel base is fixedly arranged on the outer side of the movable clamping plate, and the vessel base is attached to the vessel upper cover. According to the scheme, the problem that blood is splashed everywhere after the blood container is turned over is solved, so that the work of workers is reduced, the workers do not need to clean the workbench, and meanwhile, the smooth proceeding of a test is also ensured.